Human platelet production in NOD/SCID mice transplanted with CD34+ PBSCs
| In vivo cytokines . | Evaluation time . | No. human CD45+mice . | No. mice with human platelets (%) . | CD45, % in mice with human platelets . | CD45, % in mice without human platelets . |
|---|---|---|---|---|---|
| Placebo (PBS group) | Wk 2 | 7 | 6 (85) | 0.5, 0.62, 1, 9.5, 5.2, 2.8 | 1.5 |
| Wk 4 | 10 | 8 (80) | 0.5, 0.7, 1, 1, 1, 30, 42, 6 | 2, 2.3 | |
| Wk 8 | 8 | 6 (75) | 1, 15.9, 23, 30, 45.6, 48 | 0.8, 1 | |
| TPO, SCF, IL-3, IL-6, F13, IL-11 (6C group) | Wk 2 | 5 | 4 (80) | 3.3, 2.2, 4.3, 1 | 0.6 |
| Wk 4 | 8 | 6 (75) | 1.3, 1.9, 2, 5.2, 5.7, 3.7 | 1, 1 | |
| Wk 8 | 6 | 1 (16.6) | 26 | 1, 1.2, 1.9, 2.6, 5.7 |
| In vivo cytokines . | Evaluation time . | No. human CD45+mice . | No. mice with human platelets (%) . | CD45, % in mice with human platelets . | CD45, % in mice without human platelets . |
|---|---|---|---|---|---|
| Placebo (PBS group) | Wk 2 | 7 | 6 (85) | 0.5, 0.62, 1, 9.5, 5.2, 2.8 | 1.5 |
| Wk 4 | 10 | 8 (80) | 0.5, 0.7, 1, 1, 1, 30, 42, 6 | 2, 2.3 | |
| Wk 8 | 8 | 6 (75) | 1, 15.9, 23, 30, 45.6, 48 | 0.8, 1 | |
| TPO, SCF, IL-3, IL-6, F13, IL-11 (6C group) | Wk 2 | 5 | 4 (80) | 3.3, 2.2, 4.3, 1 | 0.6 |
| Wk 4 | 8 | 6 (75) | 1.3, 1.9, 2, 5.2, 5.7, 3.7 | 1, 1 | |
| Wk 8 | 6 | 1 (16.6) | 26 | 1, 1.2, 1.9, 2.6, 5.7 |